A REVIEW ON ALZHIMERâ€™S DISEASE: PATHOLOGY, MOLECULAR CONDITIONS, MANAGEMNT AND CAUSES
Alzheimerâ€™s disease (AD) is a neurodegenerative disorder that starts slowly, progressively leads to death and contributes to about 60-70% cases of dementia. AD is characterized with Senile Plaques (SPs) and neurofibrillary tangles (NFTs) and the major symptoms include problems with language, dis-orientation of words, unable to manage self-care, memory loss and behavioural issues which gradually lead to completely lose bodily functions later. The actual cause for the disease is not known till date. Recent research show distinct paths that closely try to reveal various cytoplasmic, genetic, behavioural, environmental and epigenetic causes that may lead to the development of AD. Most likely all studies target the Senile Plaques, protein fragments called beta-amyloid and Neurofibrillary Tangles, twisted fibres of a protein called tau. Since, the exact causative mechanism is not yet clearly understood, ultimately finding a suitable treatment or management for the disease has also become an ominous challenge for researchers.
2. Kraepelin E. Psychiatrie: EinLehrbuchfÃ¼rStudierende und Ã„rzte. Leipzig: Barth, 19:593â€“632.
3. Ballard C, Gauthier S, Corbett A, Brayne C, Aersland D, et al. Alzheimerâ€™s disease. Lancet 377; 2011: 1019-1031
4. Bird TD. Alzheimer Disease, Terry RD, Katzman R, Bick KL (eds), New York, NY: 1. Raven Press Ltd, 1994:65-74.
5. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, et al. Role of genes and environments for explaining Alzheimer disease. Arch GenPsychiatry 63; 2006: 168-174.
6. Price JL. et al. Neuropathology of non-demented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 30; 2009: 1026â€“1036.
7. Games D. et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F Î²-amyloid precursor protein. Nature 373; 1995: 523â€“527. This description of the first transgenic mouse model reliably demonstrated the amyloid plaque pathology of AD.
8. Ness D. K. et al. Reduced Î²-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months. Neurobiol. Aging25; 2004: S238â€“S239.
9. Armstrong RA, Cairns NJ, Lantos PL. Are pathological lesions in neurodegenerative disorders the cause or the effect of the degeneration? Neuropathology. 22(3); 2002:133â€“146.
10. Leslie NR. and Downes CP. PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 382; 2004: 1
11. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP. and Mak TW. Negative regulation of PKB/Aktdependent cell survival by the tumor suppressor PTEN. Cell 95; 1998: 29â€“39
12. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK. and Steck PA. Differential expression of MMAC/PTEN in glioblastomamultiforme: relationship to localization and prognosis. Cancer Res. 59; 1999: 1820â€“1824.
13. Lachyankar MB, Sultana N, Schonhoff CM, Mitra P, Poluha W, Lambert S, Quesenberry PJ, Litofsky NS, Recht LD, Nabi R, Miller SJ, Ohta S, Neel BG. and Ross AH. A role for nuclear PTEN in neuronal differentiation. J. Neurosci. 20; 200: 1404â€“1413.
14. Kyrylenko S, Roschier M, Korhonen P and Salminen A. Regulation of PTEN expression in neuronal apoptosis. Brain Res. Mol. Brain Res. 73; 1999: 198â€“202.
15. Myers, A., Holmans, P., Marshall, H., Kwon, J., Meyer, D.,Ramic, D., Shears, S., Booth, J., DeVrieze, F.W., Crook, R.,Hamshere, M., Abraham, R., Tunstall, N., Rice, F., Carty, S.,Lillystone, S., Kehoe, P., Rudrasingham, V., Jones, L., Lovestone, S., Perez-Tur, J., Williams, J., Owen, M.J., Hardy, J. andGoate, A.M. Susceptibility locus for Alzheimerâ€™s disease on chromosome 10. Science 290; 2000: 2304â€“2305.
16. Kurlawalla-Martinez C, Stiles B, Wang Y, Devaskar SU, Kahn BB, Wu H. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol Cell Biol 25; 2005: 2498â€“2510.
17. Pei JJ, Khatoon S, An WL, Nordlinder M, Tanaka T, Braak H, Tsujio I, Takeda M, Alafuzoff I, Winblad B, Cowburn RF, Grundke-Iqbal I and Iqbal K. Role of protein kinase B in Alzheimerâ€™s neurofibrillary pathology. Acta Neuropathol. (Berl) 105; 2003: 381â€“392.
18. Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R and Cowburn RF. Akt activity in Alzheimerâ€™s disease and other neurodegenerative disorders. Neuroreport 15; 2004: 955â€“959.
19. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, Oâ€™Connor R. and Oâ€™Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimerâ€™s disease pathology. J. Neurochem. 93; 2005: 105â€“117.
20. Mungarro-Menchaca X, Ferrera P, Moran J, Arias C. Beta-amyloid peptide induces ultra-structural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J Neurosci Res, 68; 2002 :89-96.
21. Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimerâ€™s dis-ease brain. J Neurosci 18; 1998: 2801-2807.
22. Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimerâ€™s disease. J Neurosci 23; 2003: 2557-2563.
23. Liu DX, Greene LA. Neuronal apop-tosis at the G1/S cell cycle checkpoint. Cell Tissue Res 305; 2001: 217-228.
24. Alzheimerâ€™s Disease and Memory Loss - A Review Naresh Korrapati1* and Naga Pavan Kumar B2 1Department of Biotechnology, Sri Krishna Devaraya University, Anantapur, India 2Livestock Research Institute, College of Veterinary Science, SVVU, Hyderabad, India
25. Birks J. Cholinesterase inhibitors for Alzheimerâ€™s disease. Cochrane Database Syst Rev. 1; 2006 : CD005593.
26. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimerâ€™s disease. Cochrane Database Syst Rev. 1; 2006: CD003476
27. PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3 Fiona Kerra, Annika Rickleb, NaushabaNayeemc, Sebastian Brandnerc, Richard F. Cowburnb, Simon Lovestone 2006: 3121â€“3128
28. Neugroschl J, Sano M. Current treatment and recent clinical research in Alzheimerâ€™s disease. Mt Sinai J Med. 77(1); 2010: 3-16.
29. Daviglus ML, Bell CC, Berrettini W, et al. NIH State-of-the-Science Conference Statement: Preventing Alzheimerâ€™s Disease and Cognitive Decline. NIH Consens State Sci Statements. 27(4); 2010: 1-27. http://consensus.nih.gov/2010/docs/alz/alz_stmt.pdf. Accessed April 29, 2010.
30. Plomin R, Owen MJ, McGuffin P.. The genetic basis of complexhumanbehaviors. Science 264; 1994: :1733â€“1739.
31. Edland SD, Silverman JM, Peskind ER, Tsuang D, Wijsman E, Morris JC. Increased risk of dementia in mothers of Alzheimerâ€™s disease cases:Evidence for maternal inheritance. Neurology 47(1); 1996: 254â€“256.
32. Bassett SS, Avramopoulos D, Perry RT, Wiener H, Watson B Jr, Go RC,Fallin MD. Further evidence of a maternal parent-of-origin effecton chromosome 10 in late-onset Alzheimerâ€™s disease. Am J Med GenetPart B 141B(5); 2006: 537â€“540.
33. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177; 200: 125â€“134.
34. Sasaoka T, Wada T, Tsuneki H. . Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity. Pharmacol.Ther 112; 2006: 799â€“809.
35. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM. Impaired insulin and insulin-like growth facÂ¬tor expression and signaling mechanisms in Alzheimerâ€™s diseaseâ€”is this type 3 diabetes. J Alzheimerâ€™s Dis 7; 2005: 63â€“80.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.